Does the media refer more to TSHA or HHH?

In the previous week, Howard Hughes had 7 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Howard Hughes and 3 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.55 beat Taysha Gene Therapies' score of 0.41 indicating that Howard Hughes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Howard Hughes 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CGON or TSHA?

In the previous week, CG Oncology had 5 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for CG Oncology and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.41 beat CG Oncology's score of 0.21 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSHA or ERAS more profitable?

Erasca's return on equity of -38.43% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Erasca N/A -38.43% -32.05%

Does the media favor TSHA or ERAS?

In the previous week, Erasca had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Erasca and 3 mentions for Taysha Gene Therapies. Erasca's average media sentiment score of 0.90 beat Taysha Gene Therapies' score of 0.41 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or TSHA?

In the previous week, Mirum Pharmaceuticals had 25 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 3 mentions for Taysha Gene Therapies. Mirum Pharmaceuticals' average media sentiment score of 0.42 beat Taysha Gene Therapies' score of 0.41 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ORKA or TSHA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Taysha Gene Therapies N/A -56.19% -41.84%

Does the media prefer ORKA or TSHA?

In the previous week, Oruka Therapeutics had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for Oruka Therapeutics and 3 mentions for Taysha Gene Therapies. Oruka Therapeutics' average media sentiment score of 0.65 beat Taysha Gene Therapies' score of 0.41 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Taysha Gene Therapies (TSHA) Competitors

$3.62 -0.11 (-2.95%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.67 +0.05 (+1.44%)

As of 10/16/2026 07:38 PM Eastern

Compare

TSHA vs. HHH, CGON, ERAS, MIRM, and ORKA

Should you buy Taysha Gene Therapies stock or one of its competitors? Taysha Gene Therapies's main competitors and comparable companies include Howard Hughes (HHH), CG Oncology (CGON), Erasca (ERAS), Mirum Pharmaceuticals (MIRM), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size.

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Howard Hughes had 7 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Howard Hughes and 3 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.55 beat Taysha Gene Therapies' score of 0.41 indicating that Howard Hughes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Howard Hughes	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 252.74%. Howard Hughes has a consensus target price of $81.00, indicating a potential upside of 17.80%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Howard Hughes has a net margin of 12.31% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 7.51% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Howard Hughes	12.31%	7.51%	2.41%

Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 47.7% of Howard Hughes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	120.73	-$109M	-$0.42	N/A
Howard Hughes	$1.47B	2.78	$123.90M	$4.94	13.92

Summary

Howard Hughes beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CG Oncology currently has a consensus target price of $87.50, suggesting a potential upside of 46.20%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 252.74%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Taysha Gene Therapies has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,313.14	-$160.99M	-$2.69	N/A
Taysha Gene Therapies	$9.77M	120.73	-$109M	-$0.42	N/A

In the previous week, CG Oncology had 5 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for CG Oncology and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.41 beat CG Oncology's score of 0.21 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Summary

Taysha Gene Therapies beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Erasca?

Taysha Gene Therapies (NASDAQ:TSHA) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

In the previous week, Erasca had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Erasca and 3 mentions for Taysha Gene Therapies. Erasca's average media sentiment score of 0.90 beat Taysha Gene Therapies' score of 0.41 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies currently has a consensus price target of $12.77, suggesting a potential upside of 252.74%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 64.98%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Erasca has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Erasca's return on equity of -38.43% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Erasca	N/A	-38.43%	-32.05%

Taysha Gene Therapies has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	120.73	-$109M	-$0.42	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

Taysha Gene Therapies beats Erasca on 10 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals currently has a consensus price target of $147.88, indicating a potential upside of 84.52%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 252.74%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mirum Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Mirum Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	9.98	-$23.36M	-$14.55	N/A
Taysha Gene Therapies	$9.77M	120.73	-$109M	-$0.42	N/A

In the previous week, Mirum Pharmaceuticals had 25 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 3 mentions for Taysha Gene Therapies. Mirum Pharmaceuticals' average media sentiment score of 0.42 beat Taysha Gene Therapies' score of 0.41 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals and Taysha Gene Therapies tied by winning 8 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Oruka Therapeutics presently has a consensus price target of $128.91, indicating a potential upside of 79.21%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 252.74%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Oruka Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Taysha Gene Therapies	$9.77M	120.73	-$109M	-$0.42	N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Oruka Therapeutics had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for Oruka Therapeutics and 3 mentions for Taysha Gene Therapies. Oruka Therapeutics' average media sentiment score of 0.65 beat Taysha Gene Therapies' score of 0.41 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Summary

Taysha Gene Therapies beats Oruka Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.22B	$3.95B	$7.45B	$12.95B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	-8.62	12.55	275.00	24.84
Price / Sales	120.73	1,175.03	571.54	76.68
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	4.02	15.94	10.31	5.85
Net Income	-$109M	-$22.69M	$3.51B	$381.63M
7 Day Performance	-19.38%	-8.71%	-5.47%	-5.04%
1 Month Performance	-29.84%	-15.43%	-9.66%	-7.99%
1 Year Performance	-23.31%	1.39%	0.73%	-5.68%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	2.1445 of 5 stars	$3.62 -2.9%	$12.77 +252.7%	-28.7%	$1.22B	$9.77M	N/A	99
HHH Howard Hughes	3.4479 of 5 stars	$72.33 -1.9%	$81.00 +12.0%	-13.7%	$4.40B	$1.47B	14.64	500	Analyst Upgrade
CGON CG Oncology	3.6703 of 5 stars	$63.13 -1.1%	$87.50 +38.6%	+43.0%	$5.66B	$4.04M	N/A	142	Analyst Forecast
ERAS Erasca	2.7565 of 5 stars	$15.46 -3.6%	$22.09 +42.9%	+429.2%	$5.61B	N/A	N/A	103	News Coverage Positive News
MIRM Mirum Pharmaceuticals	3.153 of 5 stars	$86.06 +0.1%	$146.13 +69.8%	+7.7%	$5.58B	$521.31M	N/A	433	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, CGON, ERAS, MIRM, and ORKA

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Summary

How does Taysha Gene Therapies compare to Erasca?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, CGON, ERAS, MIRM, and ORKA

How does Taysha Gene Therapies compare to Howard Hughes?

Does the media refer more to TSHA or HHH?

Do analysts prefer TSHA or HHH?

Is TSHA or HHH more profitable?

Which has more volatility & risk, TSHA or HHH?

Do insiders & institutionals have more ownership in TSHA or HHH?

Which has preferable valuation and earnings, TSHA or HHH?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Do institutionals and insiders have more ownership in CGON or TSHA?

Do analysts rate CGON or TSHA?

Which has better earnings and valuation, CGON or TSHA?

Does the media prefer CGON or TSHA?

Is CGON or TSHA more profitable?

Which has more volatility & risk, CGON or TSHA?

Summary

How does Taysha Gene Therapies compare to Erasca?

Does the media favor TSHA or ERAS?

Do analysts prefer TSHA or ERAS?

Which has more volatility and risk, TSHA or ERAS?

Do insiders and institutionals hold more shares of TSHA or ERAS?

Is TSHA or ERAS more profitable?

Which has higher valuation and earnings, TSHA or ERAS?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Do institutionals & insiders have more ownership in MIRM or TSHA?

Do analysts recommend MIRM or TSHA?

Which has more volatility & risk, MIRM or TSHA?

Is MIRM or TSHA more profitable?

Which has higher earnings & valuation, MIRM or TSHA?

Does the media prefer MIRM or TSHA?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Do analysts rate ORKA or TSHA?

Is ORKA or TSHA more profitable?

Which has stronger earnings & valuation, ORKA or TSHA?

Do insiders and institutionals have more ownership in ORKA or TSHA?

Does the media prefer ORKA or TSHA?

Which has more risk and volatility, ORKA or TSHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools